@Article{,
AUTHOR = {Andrea Lo, Robert K. Nam, D. Andrew Loblaw},
TITLE = {HDR monotherapy for man with radiotherapy contraindications and prostate cancer},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {18},
YEAR = {2011},
NUMBER = {4},
PAGES = {5839--5843},
URL = {http://www.techscience.com/CJU/v18n4/61903},
ISSN = {1488-5581},
ABSTRACT = {There is debate about the optimal management of high risk localized prostate cancer.  Initial options include surgery or radiation combined with androgen deprivation therapy. We describe a case of a patient with contraindications to radiotherapywhowasmanagedwithhighdoserate(HDR) brachytherapy as his sole treatment.<br/>
A medically operable patient presented with a T2c N0 M0 Gleason9adenocarcinomawithaninitialPSAof19.9ng/mL. Previously, he had severe ulcerative colitis managed with pancolectomy and a neorectum fashioned from ileum anastomosedbehindhisprostate.Afteranegativeextended lymph node dissection, a HDR brachytherapy implant of 35Gyin5fractionsover3dayswasdelivered.Noandrogen deprivationtherapywasused.Thetreatmentwasextremely welltoleratedintheshortandlongtermwithnosignificant bowel or bladder side effects observed in follow up.  After 7 years, his PSA was 0.04 ng/mL.<br/>
The excellent long-term biochemical control and minimal radiation toxicity observed in this patient suggests that HDR monotherapy may be a safe and effective alternative for high risk prostate cancer patients in whom EBRT is contraindicated.},
DOI = {}
}